Johnson & Johnson vs. Eli Lilly: Comparing Stability and Growth in Pharmaceuticals
Johnson & Johnson (JNJ) is a diversified healthcare company known for stable revenue growth and strong financial performance, with a recent acquisition of Firefly Bio and a net income margin of about 22% as of June 28, 2026. The stock currently trades at $266.73 (+0.29%) with a market cap of $643 billion. Eli Lilly (LLY) is experiencing rapid revenue growth driven by its diabetes and obesity treatments like Mounjaro and Zepbound, along with the recent acquisition of Centessa Pharmaceuticals. The company reported a 37% net income margin for March 2026 and trades at $1,221.45 (+2.00%) with a market cap exceeding $1 trillion. Both companies are expanding through strategic acquisitions but differ in growth trajectories: J&J offers reliable dividends (1.96%), while LLY is scaling faster despite paying a smaller yield of 0.53%. Investors should monitor patent risks and competitive pressures, especially for Lilly as it continues to close the gap with Johnson & Johnson.
